Management

Craig Collard
Chief Executive Officer

Ira Duarte
Executive Vice President, Chief Financial Officer

William Forbes
Executive Vice President, Chief Development Officer

Brett Fleshman
Chief Business Officer

Kevin Warner, PharmD
Senior Vice President, Medical Affairs Strategy and Engagement

John Arthur, Ph.D.
Senior Vice President, Manufacturing & Supply

Robert Sullivan
Senior Vice President, Oncology Care Franchise and Commercial Operations

Ryan Craig
Vice President, Marketing

David Barozzino
Vice President of Sales – Acute Care

Craig Collard

Chief Executive Officer

Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., “Veloxis”) before it was acquired by Asahi Kasei Corp, a transplant-focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company (“Cornerstone”), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. in 2014. Mr. Collard also served as Cornerstone’s Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. Mr. Collard currently serves on the board of directors of TerrAscend Corp., a North American cannabis operator based in Mississauga, Canada, since December 2018. Mr. Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May 2020 to July 2022. He also served as Chairman of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapies to treat substance and use disorders and drug overdose since October 2018 until being acquired by Indivior on March 1, 2023. Mr. Collard holds a B.S. in Engineering from the Southern College of Technology (now Southern Polytechnic State University).

Back to top

Ira Duarte

Executive Vice President, Chief Financial Officer

Ira Duarte joined Heron as Executive Vice President, Chief Financial Officer in June 2023. Ms. Duarte brings significant experience and expertise in financial leadership to Heron. Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 to 2023, most recently as Chief Financial Officer, at Veloxis Pharmaceuticals, Inc., a fully integrated specialty pharmaceutical company. Prior to that, Ms. Duarte served as the Corporate Controller at BioDelivery Sciences, Inc. from 2014 to 2016, and from 2009 to 2014 she was Senior Director of Corporate Finance for Chiesi USA, Inc. and Director of Accounting and Financial Planning for Cornerstone Therapeutics, Inc., where she was a core member of the team that guided the sale of Cornerstone Therapeutics, Inc. to Chiesi Farmaceutici S.p.A. Ms. Duarte previously held various roles from Staff to Senior Manager at Ernst & Young Global Limited. Ms. Duarte currently serves on the board of directors of TerrAscend Corporation and has since December 2022. Ms. Duarte is a Certified Public Accountant and holds a B.S. in Accounting from Florida Atlantic University.

Back to top

William Forbes

Executive Vice President, Chief Development Officer

William Forbes has served as our Executive Vice President, Chief Development Officer since June 2023. Dr. Forbes brings more than thirty years of pharmaceutical product development experience to Heron and has contributed to 14 marketing approvals spanning a diverse range of therapeutic areas in the U.S. and European markets. Prior to joining Heron, Dr. Forbes served as the Chief Development Officer at Trevi Therapeutics, Inc. from 2021 to 2022. From 2016 to 2020, Dr. Forbes served as the President and CEO of Vivelix Pharmaceuticals, Ltd., where he was the founder and responsible for all strategic and operational aspects of the organization. Prior to that, Dr. Forbes served as the Chief Development Officer at Salix Pharmaceuticals, Inc. as the Head of Medical and R&D from 2005 to 2015. Earlier in his career, Dr. Forbes held various positions in clinical research and development at Metabasis Therapeutics, Inc., Otsuka America Pharmaceuticals, Inc., and Glaxo, Inc. Dr. Forbes received his Doctor of Pharmacy degree from Creighton University, and he completed fellowships in cardiovascular research at Creighton Cardiac Center and in clinical research at Glaxo, Inc.

Back to top

Brett Fleshman

Chief Business Officer

Brett Fleshman joined Heron as Chief Business Officer in August 2024. Mr. Fleshman contributes 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team, further enabling the company’s next phase of growth. Prior to joining Heron, Brett Fleshman served as Managing Director at NovaQuest Capital Management, a leader in product-based financing for late-stage clinical and commercial biopharmaceutical programs where he was responsible for deal sourcing, structuring nondilutive investments, negotiations, diligence, and post-close investment management. Prior to NovaQuest, Mr. Fleshman served as Vice President of Strategy and Corporate Development for Veloxis Pharmaceuticals, where he helped formulate a turnaround commercialization strategy which led to the company’s acquisition in 2020 by Asahi Kasei. Previously, Mr. Fleshman held senior commercial and business development roles at Cornerstone Therapeutics, supporting numerous company acquisitions, asset purchases and territory licenses to build thriving hospital and rare disease businesses that helped lead to the company’s acquisition by Chiesi Pharmaceutici S.p.A. Mr. Fleshman also held senior marketing roles at Ther-Rx Corporation and Genzyme Biosurgery, now Sanofi Genzyme. Throughout his career, Mr. Fleshman has focused on developing efficient strategies for commercializing new products and revitalizing distressed assets. Mr. Fleshman earned a degree in Business Administration from the John M. Olin School of Business at Washington University in St. Louis.

Back to top

Kevin Warner, PharmD

Senior Vice President, Medical Affairs Strategy and Engagement

Dr. Kevin Warner began working as Senior Vice President of Medical Affairs Strategy and Engagement with Heron Therapeutics in 2024. Prior to that, he had served as a consultant/advisor and was on the speaker’s bureau with Heron Therapeutics since 2022. Dr. Warner has been Director of Pharmaceutical Sciences for Osteal Therapeutics since 2015. He is the co-developer of VT-X7 intra-articular antibiotic irrigation therapy for the treatment of peri-prosthetic joint infection with the primary responsibility for dosing, administration, and monitoring. In addition to his responsibilities at Heron Therapeutics and Osteal Therapeutics, Dr. Warner is a clinical staff pharmacist at Covenant Healthcare, a 650-bed teaching hospital in Saginaw, MI, and home infusion pharmacist at Covenant HealthCare VNA Home Infusion. Dr. Warner has over 15 years of experience in clinical and infusion pharmacy with a special focus on in pharmacokinetics, pharmacodynamics and perioperative medicine. Dr. Warner received his Doctor of Pharmacy degree from Ferris State University in Big Rapids, MI.

Back to top

John Arthur, Ph.D

Senior Vice President, Manufacturing & Supply

John Arthur, Ph.D. joined Heron as Vice President of Manufacturing and Supply in 2017. Dr. Arthur has more than 20 years of experience in pharmaceutical manufacturing. From 2013 to 2016, he was Vice President of Manufacturing and CMC at Mast Therapeutics, Inc., where he led all CMC activities for multiple Phase 2 and Phase 3 clinical programs. From 2012 to 2013, Dr. Arthur was Senior Director of Manufacturing at Auspex Pharmaceuticals, Inc. Prior to his role at Auspex, he held several positions of increasing responsibility at various biopharmaceutical companies, including Cadence Pharmaceuticals, Inc., Kanisa Pharmaceuticals, Inc., Salmedix, Inc., Prometheus Laboratories Inc., Maxim Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. Dr. Arthur received a B.S. in Biochemistry from Western Washington University, a Ph.D. in organic chemistry from the University of South Carolina, Columbia and conducted his postdoctoral research at Michigan State University.

Back to top

Robert Sullivan

Senior Vice President, Oncology Care Franchise and Commercial Operations

Robert Sullivan joined Heron as Senior Director, Oncology Commercial Operations in 2017. He was promoted to Vice President, Contracting and Commercial Operations in 2020, then to Senior Vice President, Oncology Care Franchise and Commercial Operations in 2023. Mr. Sullivan has more than 20 years of experience serving in various leadership positions in Sales, Operations and Market Access with biotechnology companies and group purchasing organizations. From 2007 to 2017, Mr. Sullivan held various positions of increasing responsibility with the International Oncology Network (ION), a division of AmerisourceBergen. He received a B.S. degree in business administration, management from Towson University.

Back to top

Ryan Craig

Vice President, Marketing

Ryan Craig joined Heron in August 2023 as Vice President of Marketing. He has more than 22 years of pharmaceutical industry experience in a variety of commercial positions including sales, marketing, market access, training, and corporate strategy. Ryan spent 15 years at Salix Pharmaceuticals progressing from Product Manager to Associate Director of Marketing at the time that Salix was
acquired in 2015. He has managed and led numerous product launches across categories including gastroenterology, hepatology, endocrinology, neuroscience, pain, infectious disease, and solid-organ transplant. Prior to joining Heron, Ryan was VP, Marketing and Corporate Strategy at Veloxis Pharmaceuticals. Ryan holds a BS in Business Administration, with a concentration in Marketing from Radford University.

Back to top

David Barozzino

Vice President of Sales – Acute Care

David Barozzino was hired at Heron in Feb 2019 to help commercialize the build out of the sales force and to
launch ZYNRELEF and APONVIE. Prior to Heron, David held numerous roles as Sr. Area Sales Director,
Area Vice President of Sales, Sr Product Manager, Regional Sales Manager and carried the sales bag. He
brings more than 20 years’ experience across both pharma and medical sales in sales leadership,
product launches, sales force expansion, brand management, marketing, and market access. David has
been part of the scale up at four different biotech companies from the ground up. David holds a BA in Business Administration from the University of Massachusetts Lowell.